Sanofi SA and its partner GlaxoSmithKline Plc are to test a new antigen formulation for their Covid-19 vaccine in order to generate a better response from older adults. Assuming all data are positive, the vaccine would be available in the 2021 fourth quarter rather than mid-2021, the companies announced on 11 December 2020.
